Novel Levoglucosenone Derivatives: Preclinical Evaluation in Breast Cancer Models.
The antitumor activity of three levoglucosenone-based derivatives in preclinical breast cancer models demonstrated that two of the derivatives significantly inhibited tumor growth and metastatic dissemination without evidence of systemic toxicity, indicating a promising synergistic effect.